Nektar Therapeutics Shares Drop as Jury Deliberates in Eli Lilly Patent Case

Key Facts

1Nektar Therapeutics shares declined as a jury began deliberations in a patent dispute case against Eli Lilly regarding the drug Rezpeg.

Amid heightened sensitivity in the biotech sector toward litigation, Nektar Therapeutics shares declined as its legal battle against Eli Lilly moved into the final deliberation phase. The case centers on a patent dispute regarding the drug Rezpeg, with a federal jury now weighing the evidence to reach a verdict. This decline reflects market concerns over legal uncertainty that could impact the company's future revenues and intellectual property rights associated with the treatment.

According to market data, Nektar Therapeutics (NKTR) closed at $66.84 (close September 21, 2026), exhibiting notable volatility as investors await the jury's decision. Meanwhile, Eli Lilly (LLY) stood at $1169.7 at the close of September 22, 2026, with a daily trading range between $1139.37 and $1180.53. Markets are closely monitoring the outcome of this dispute given the significant disparity in market capitalization between the two firms and the potential impact of the ruling on their operational strategies.

Traders should watch for any court announcements regarding the verdict, as the jury's decision represents the primary catalyst for the stock's near-term direction. Based on price levels recorded on September 21, 2026, NKTR faces technical pressure near its daily low of $66.71. With no major upcoming economic calendar events directly impacting the sector, focus remains entirely on the legal developments in San Francisco.